55

Ko 143

55 Publications Verification

Cat. No.: HY-10010

CAS No.: 461054-93-3

Purity: 99.97%

Target:

BCRP

Research Areas:

Cancer

Ko 143 is a potent and selective ATP-binding cassette subfamily G member 2 (ABCG2/BCRP) inhibitor. Ko 143 displays >200-fold selectivity over P-gp and MRP-1 transporters .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

32

Elacridar

32 Cited Publications

Cat. No.: HY-50879

CAS No.: 143664-11-3

Synonyms: GF120918; GW0918; GG918; GW120918

Target:

P-glycoprotein BCRP

Research Areas:

Cancer

Elacridar is an orally active P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar can be used to examine the influence of efflux transporters on agent distribution to brain and the research of cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

32

Elacridar hydrochloride

32 Cited Publications

Cat. No.: HY-50880

CAS No.: 143851-98-3

Synonyms: GF120918A

Target:

P-glycoprotein BCRP

Research Areas:

Cancer

Elacridar hydrochloride (GF120918A) is an orally active P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar hydrochloride can be used to examine the influence of efflux transporters on agent distribution to brain and it can be used for the research of cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

13

Elrelesertib

13 Cited Publications

Cat. No.: HY-109566

CAS No.: 2089288-03-7

Purity: 99.22%

Synonyms: AZD1390

Target:

ATM/ATR Apoptosis Checkpoint Kinase (Chk)

Research Areas:

Cancer

Elrelesertib (AZD1390) is an orally active, brain-penetrant ATM kinase inhibitor with IC₅₀ values of 0.78 nM. Elrelesertib blocks ATM-dependent DNA damage response, inhibits ATM autophosphorylation and downstream Chk2, Rad50 phosphorylation, and accumulates at DNA breaks. Elrelesertib acts as a radiosensitizer, induces apoptosis, genomic instability, G2-M cell cycle arrest, ROS elevation, and mitochondrial membrane potential alteration. Elrelesertib has low efflux liability against P-gp and BCRP. Elrelesertib can be used for the research of central nervous system malignancies, glioblastoma multiforme, glioma, lung cancer brain metastases, and breast cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

9

CP-100356 hydrochloride

9 Cited Publications

Cat. No.: HY-108347

CAS No.: 142715-48-8

Purity: 99.19%

Target:

P-glycoprotein BCRP

Research Areas:

Metabolic Disease

CP-100356 hydrochloride is an orally active dual MDR1 (P-gp)/BCRP inhibitor, with an IC₅₀s of 0.5 and 1.5 µM for inhibiting MDR1-mediated Calcein-AM transport and BCRP-mediated Prazosin transport, respectively. CP-100356 hydrochloride is also a weak inhibitor of OATP1B1 (IC₅₀=∼66 µM). CP-100356 hydrochloride is devoid of inhibition against MRP2 and major human P450 enzymes (IC₅₀>15 µM) .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

Pradigastat

2 Cited Publications

Cat. No.: HY-16278

CAS No.: 956136-95-1

Synonyms: LCQ-908

Target:

Acyltransferase BCRP OAT

Research Areas:

Infection Metabolic Disease

Pradigastat (LCQ-908) is a selective and orally effective diacylglyceryl acyltransferase 1 (DGAT1) inhibitor with IC₅₀ at 0.157 µM. Pradigastat is primarily used to study diseases associated with abnormal triglyceride metabolism. Pradigastat has anti-obesity and anti-diabetic effects. Pradigastat inhibited BCRP, OATP1B1, OATP1B3 and OAT3 activities with IC₅₀ of 5 µM, 1.66µM, 3.34µM and 0.973µM, respectively. In addition, Pradigastat has antiviral activity and can inhibit hepatitis C virus replication in vitro .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

YHO-13177

2 Cited Publications

Cat. No.: HY-12757

CAS No.: 912287-56-0

Purity: 99.65%

Target:

BCRP

Research Areas:

Cancer

YHO-13177, a acrylonitrile derivative, is an orally active, potent and specific inhibitor of breast cancer resistance protein (BCRP) and ABCG2 with an IC₅₀ value of 10 nM. YHO-13177 potentiates the cytotoxicity of SN-38 in HCT116 and A549 cells that express BCRP. YHO-13177 combined with Irinotecan (HY-16562) significantly suppresses the tumor growth in an HCT116/BCRP xenograft model .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

KS176

2 Cited Publications

Cat. No.: HY-19753

CAS No.: 1253452-78-6

Target:

BCRP

Research Areas:

Cancer

KS176 is a selective BCRP inhibitor (IC₅₀ values are 0.59 and 1.39 μM in Pheo A and Hoechst assays, respectively). KS176 can be used in the research of cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

Moxidectin

1 Cited Publications

Cat. No.: HY-B0777

CAS No.: 113507-06-5

Synonyms: CL301423

Target:

Antibiotic BCRP P-glycoprotein Parasite

Research Areas:

Infection Neurological Disease

Moxidectin (CL301423) is an orally active and brain-penetrant macrolide (ML) anthelmintic for the prevention and control of heartworms and roundworms. Moxidectin is also a substrate of BCRP and P-glycoprotein (P-gp) in vivo, and is secreted into breast milk and effluxed from the host and parasite mediated by Bcrp1 and P-gp. This may be related to the presence of chemical residues in milk .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

5,7-Dimethoxyflavone

1 Cited Publications

Cat. No.: HY-N5011

CAS No.: 21392-57-4

Category:

Flavonoids Zingiberaceae Extract Flavones 500 - Internal Server Error | MedChemExpress

country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Cart

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Oops!

Sorry, Something went wrong on our server.
Our team has been notified and is working to fix the issue.